Does the media refer more to SERA or SABS?

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, IFRX or SERA?

Sera Prognostics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx -$10.10K -28,595.32 -$51.63M -$0.58 N/A Sera Prognostics $80K 1,015.84 -$31.93M -$0.67 N/A

Is IFRX or SERA more profitable?

InflaRx has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Sera Prognostics -47,475.72% -46.71% -34.06%

Does the media refer more to IFRX or SERA?

In the previous week, InflaRx had 2 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for InflaRx and 1 mentions for Sera Prognostics. InflaRx's average media sentiment score of 0.34 beat Sera Prognostics' score of 0.00 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ABEO or SERA?

In the previous week, Abeona Therapeutics had 15 more articles in the media than Sera Prognostics. MarketBeat recorded 16 mentions for Abeona Therapeutics and 1 mentions for Sera Prognostics. Abeona Therapeutics' average media sentiment score of 0.61 beat Sera Prognostics' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SERA or FULC?

In the previous week, Fulcrum Therapeutics had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 1 mentions for Sera Prognostics. Fulcrum Therapeutics' average media sentiment score of 0.26 beat Sera Prognostics' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PYXS or SERA?

In the previous week, Pyxis Oncology had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Sera Prognostics. Pyxis Oncology's average media sentiment score of 0.00 equaled Sera Prognostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sera Prognostics (SERA) Competitors

$2.06 -0.07 (-3.29%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.00 (+0.24%)

As of 09/23/2026 04:10 PM Eastern

Compare

SERA vs. SABS, IFRX, ABEO, FULC, and PYXS

Should you buy Sera Prognostics stock or one of its competitors? Sera Prognostics's main competitors and comparable companies include SAB Biotherapeutics (SABS), InflaRx (IFRX), Abeona Therapeutics (ABEO), Fulcrum Therapeutics (FULC), and Pyxis Oncology (PYXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sera Prognostics compare to SAB Biotherapeutics?

Sera Prognostics (NASDAQ:SERA) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Sera Prognostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Sera Prognostics currently has a consensus target price of $5.50, indicating a potential upside of 166.99%. SAB Biotherapeutics has a consensus target price of $12.00, indicating a potential upside of 253.98%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SAB Biotherapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,015.84	-$31.93M	-$0.67	N/A
SAB Biotherapeutics	$1.32M	233.68	$13.27M	-$1.30	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. SAB Biotherapeutics' return on equity of -6.74% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

Summary

SAB Biotherapeutics beats Sera Prognostics on 10 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Sera Prognostics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	-$10.10K	-28,595.32	-$51.63M	-$0.58	N/A
Sera Prognostics	$80K	1,015.84	-$31.93M	-$0.67	N/A

InflaRx currently has a consensus target price of $7.43, suggesting a potential upside of 279.01%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 166.99%. Given InflaRx's higher possible upside, equities analysts plainly believe InflaRx is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

InflaRx has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

42.4% of InflaRx shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, InflaRx had 2 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for InflaRx and 1 mentions for Sera Prognostics. InflaRx's average media sentiment score of 0.34 beat Sera Prognostics' score of 0.00 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InflaRx has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Summary

InflaRx beats Sera Prognostics on 8 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Abeona Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Abeona Therapeutics' return on equity of -41.69% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Abeona Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 279.75%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 166.99%. Given Abeona Therapeutics' higher possible upside, equities research analysts plainly believe Abeona Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Abeona Therapeutics has higher revenue and earnings than Sera Prognostics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	54.33	$71.18M	-$1.09	N/A
Sera Prognostics	$80K	1,015.84	-$31.93M	-$0.67	N/A

Abeona Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

In the previous week, Abeona Therapeutics had 15 more articles in the media than Sera Prognostics. MarketBeat recorded 16 mentions for Abeona Therapeutics and 1 mentions for Sera Prognostics. Abeona Therapeutics' average media sentiment score of 0.61 beat Sera Prognostics' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Abeona Therapeutics beats Sera Prognostics on 11 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Fulcrum Therapeutics?

Sera Prognostics (NASDAQ:SERA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Fulcrum Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Fulcrum Therapeutics' return on equity of -25.38% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

Sera Prognostics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the broader market.

Sera Prognostics presently has a consensus price target of $5.50, suggesting a potential upside of 166.99%. Fulcrum Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 115.22%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities analysts plainly believe Sera Prognostics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Sera Prognostics has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,015.84	-$31.93M	-$0.67	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A

In the previous week, Fulcrum Therapeutics had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 1 mentions for Sera Prognostics. Fulcrum Therapeutics' average media sentiment score of 0.26 beat Sera Prognostics' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Sera Prognostics beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Pyxis Oncology has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Pyxis Oncology presently has a consensus target price of $8.75, suggesting a potential upside of 171.74%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 166.99%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Pyxis Oncology had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Sera Prognostics. Pyxis Oncology's average media sentiment score of 0.00 equaled Sera Prognostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pyxis Oncology has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Sera Prognostics has lower revenue, but higher earnings than Pyxis Oncology. Sera Prognostics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	19.38	-$79.62M	-$1.41	N/A
Sera Prognostics	$80K	1,015.84	-$31.93M	-$0.67	N/A

Summary

Pyxis Oncology and Sera Prognostics tied by winning 8 of the 16 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.03M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-3.07	13.88	274.01	25.69
Price / Sales	1,015.84	1,382.00	656.83	89.15
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.06	15.30	10.44	6.32
Net Income	-$31.93M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-0.48%	-1.71%	-0.66%	0.17%
1 Month Performance	-5.50%	-6.17%	-3.16%	-3.27%
1 Year Performance	-33.33%	30.64%	15.15%	5.58%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	1.9043 of 5 stars	$2.06 -3.3%	$5.50 +167.0%	-33.3%	$84.03M	$80K	N/A	72
SABS SAB Biotherapeutics	1.9991 of 5 stars	$3.41 -1.4%	$12.00 +251.9%	+50.0%	$314.81M	$1.32M	N/A	86	News Coverage
IFRX InflaRx	1.7426 of 5 stars	$2.02 -4.7%	$7.43 +267.8%	+50.8%	$312.42M	$30K	N/A	65	Analyst Forecast
ABEO Abeona Therapeutics	2.8049 of 5 stars	$5.47 +0.7%	$19.33 +253.4%	+0.4%	$310.51M	$5.82M	N/A	226
FULC Fulcrum Therapeutics	2.4261 of 5 stars	$3.78 -0.3%	$8.20 +116.9%	-48.2%	$289.17M	$80M	N/A	55

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. SABS, IFRX, ABEO, FULC, and PYXS

How does Sera Prognostics compare to SAB Biotherapeutics?

Summary

How does Sera Prognostics compare to InflaRx?

Summary

How does Sera Prognostics compare to Abeona Therapeutics?

Summary

How does Sera Prognostics compare to Fulcrum Therapeutics?

Summary

How does Sera Prognostics compare to Pyxis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. SABS, IFRX, ABEO, FULC, and PYXS

How does Sera Prognostics compare to SAB Biotherapeutics?

Which has more volatility & risk, SERA or SABS?

Do analysts recommend SERA or SABS?

Do insiders and institutionals believe in SERA or SABS?

Does the media refer more to SERA or SABS?

Which has higher earnings and valuation, SERA or SABS?

Is SERA or SABS more profitable?

Summary

How does Sera Prognostics compare to InflaRx?

Which has better valuation & earnings, IFRX or SERA?

Do analysts recommend IFRX or SERA?

Which has more risk & volatility, IFRX or SERA?

Do insiders & institutionals have more ownership in IFRX or SERA?

Does the media refer more to IFRX or SERA?

Is IFRX or SERA more profitable?

Summary

How does Sera Prognostics compare to Abeona Therapeutics?

Do insiders and institutionals believe in ABEO or SERA?

Is ABEO or SERA more profitable?

Do analysts recommend ABEO or SERA?

Which has higher valuation & earnings, ABEO or SERA?

Which has more risk and volatility, ABEO or SERA?

Does the media prefer ABEO or SERA?

Summary

How does Sera Prognostics compare to Fulcrum Therapeutics?

Is SERA or FULC more profitable?

Which has more risk & volatility, SERA or FULC?

Do analysts recommend SERA or FULC?

Which has higher valuation & earnings, SERA or FULC?

Does the media refer more to SERA or FULC?

Do insiders & institutionals hold more shares of SERA or FULC?

Summary

How does Sera Prognostics compare to Pyxis Oncology?

Is PYXS or SERA more profitable?

Do analysts rate PYXS or SERA?

Does the media prefer PYXS or SERA?

Do institutionals & insiders have more ownership in PYXS or SERA?

Which has more risk & volatility, PYXS or SERA?

Which has stronger valuation and earnings, PYXS or SERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools